Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19828211 | 0.85 | LTA4H (0.44) | HRH1 | |
| SCHEMBL19822547 | 0.81 | TAAR1 (0.35) | CYP2A6TAAR1 | |
| SCHEMBL6912141 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL6912142 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL501840 | 0.76 | TRPA1 (0.31) | — | |
| SCHEMBL21048436 | 0.73 | XPO1 (0.52) | CYP2A6 | |
| SCHEMBL19822504 | 0.73 | XPO1 (0.52) | CYP2A6 | |
| SCHEMBL19828162 | 0.70 | IDO1 (0.36) | TAAR1 | |
| SCHEMBL19822543 | 0.70 | ALDH1A1 (0.45) | SMN1; SMN2 | |
| SCHEMBL777022 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | DRIVINGFORCE THERAPEUTICS (CN) | 2019-06-11 | — | — | US | disclosed |
| US-20180029979-A1 | ISOTHIOCYANATE COMPOUND AND APPLICATION THEREOF | DRIVINGFORCE THERAPEUTICS Co., Ltd. (CN) | 2018-02-01 | — | — | US | disclosed |
| US-20180029979-A1 | ISOTHIOCYANATE COMPOUND AND APPLICATION THEREOF | DRIVINGFORCE THERAPEUTICS Co., Ltd. (CN) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | XPO1, XPOT, XPO4 | CYP2A6 1221/4885HTR2A 4112/4885SMN1; SMN2 3357/4885 |
| US-20180029979-A1 | ISOTHIOCYANATE COMPOUND AND APPLICATION THEREOF | XPO1, XPOT, XPO4 | CYP2A6 1030/4885HTR2A 4094/4885SMN1; SMN2 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.